Literature DB >> 28602601

Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

Vincent Chouraki1, Sarah R Preis2, Qiong Yang2, Alexa Beiser3, Shuo Li2, Martin G Larson2, Galit Weinstein4, Thomas J Wang5, Robert E Gerszten6, Ramachandran S Vasan7, Sudha Seshadri8.   

Abstract

INTRODUCTION: The identification of novel biomarkers associated with Alzheimer's disease (AD) could provide key biological insights and permit targeted preclinical prevention. We investigated circulating metabolites associated with incident dementia and AD using metabolomics.
METHODS: Plasma levels of 217 metabolites were assessed in 2067 dementia-free Framingham Offspring Cohort participants (mean age = 55.9 ± 9.7 years; 52.4% women). We studied their associations with future dementia and AD risk in multivariate Cox models.
RESULTS: Ninety-three participants developed incident dementia (mean follow-up = 15.6 ± 5.2 years). Higher plasma anthranilic acid levels were associated with greater risk of dementia (hazard ratio [HR] = 1.40; 95% confidence interval [CI] = [1.15-1.70]; P = 8.08 × 10-4). Glutamic acid (HR = 1.38; 95% CI = [1.11-1.72]), taurine (HR = 0.74; 95% CI = [0.60-0.92]), and hypoxanthine (HR = 0.74; 95% CI = [0.60-0.92]) levels also showed suggestive associations with dementia risk. DISCUSSION: We identified four biologically plausible, candidate plasma biomarkers for dementia. Association of anthranilic acid implicates the kynurenine pathway, which modulates glutamate excitotoxicity. The associations with hypoxanthine and taurine strengthen evidence that uric acid and taurine may be neuroprotective.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Anthranilic acid; Cohort studies; Dementia; Epidemiology; Glutamic acid; Hypoxanthine; Kynurenines; Metabolomics; Plasma biomarkers; Taurine; Uric acid

Mesh:

Substances:

Year:  2017        PMID: 28602601      PMCID: PMC5722716          DOI: 10.1016/j.jalz.2017.04.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  55 in total

Review 1.  Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis.

Authors:  Ben Ellis; Abdul Hye; Stuart G Snowden
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  Immune attack: the role of inflammation in Alzheimer disease.

Authors:  Frank L Heppner; Richard M Ransohoff; Burkhard Becher
Journal:  Nat Rev Neurosci       Date:  2015-06       Impact factor: 34.870

3.  Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Authors:  Daniel Zwilling; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Paolo Guidetti; Hui-Qiu Wu; Jason Lee; Jennifer Truong; Yaisa Andrews-Zwilling; Eric W Hsieh; Jamie Y Louie; Tiffany Wu; Kimberly Scearce-Levie; Christina Patrick; Anthony Adame; Flaviano Giorgini; Saliha Moussaoui; Grit Laue; Arash Rassoulpour; Gunnar Flik; Yadong Huang; Joseph M Muchowski; Eliezer Masliah; Robert Schwarcz; Paul J Muchowski
Journal:  Cell       Date:  2011-06-10       Impact factor: 41.582

Review 4.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

5.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

7.  New norms for a new generation: cognitive performance in the framingham offspring cohort.

Authors:  Rhoda Au; Sudha Seshadri; Philip A Wolf; Merrill Elias; Penelope Elias; Lisa Sullivan; Alexa Beiser; Ralph B D'Agostino
Journal:  Exp Aging Res       Date:  2004 Oct-Dec       Impact factor: 1.645

8.  Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.

Authors:  Markus J Schwarz; Gilles J Guillemin; Stefan J Teipel; Katharina Buerger; Harald Hampel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-11-29       Impact factor: 5.270

9.  MetaboAnalyst 3.0--making metabolomics more meaningful.

Authors:  Jianguo Xia; Igor V Sinelnikov; Beomsoo Han; David S Wishart
Journal:  Nucleic Acids Res       Date:  2015-04-20       Impact factor: 16.971

10.  Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.

Authors:  Carlo Breda; Korrapati V Sathyasaikumar; Shama Sograte Idrissi; Francesca M Notarangelo; Jasper G Estranero; Gareth G L Moore; Edward W Green; Charalambos P Kyriacou; Robert Schwarcz; Flaviano Giorgini
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

View more
  30 in total

1.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

Review 2.  Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology.

Authors:  Sophie Lefèvre-Arbogast; Maude Wagner; Cécile Proust-Lima; Cécilia Samieri
Journal:  Curr Nutr Rep       Date:  2019-09

3.  High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease.

Authors:  Tommaso Nuzzo; Andrea Mancini; Mattia Miroballo; Alessia Casamassa; Anna Di Maio; Giorgia Donati; Giulia Sansone; Lorenzo Gaetani; Federico Paolini Paoletti; Andrea Isidori; Paolo Calabresi; Francesco Errico; Lucilla Parnetti; Alessandro Usiello
Journal:  Amino Acids       Date:  2021-02-22       Impact factor: 3.520

4.  Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function.

Authors:  J Scott Lee; Ruth X Wang; Erica E Alexeev; Jordi M Lanis; Kayla D Battista; Louise E Glover; Sean P Colgan
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

5.  Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.

Authors:  Zhiguang Huo; Lei Yu; Jingyun Yang; Yun Zhu; David A Bennett; Jinying Zhao
Journal:  Neurobiol Aging       Date:  2019-11-05       Impact factor: 4.673

6.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

7.  Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study.

Authors:  Pratishtha Chatterjee; Kathryn Goozee; Chai K Lim; Ian James; Kaikai Shen; Kelly R Jacobs; Hamid R Sohrabi; Tejal Shah; Prita R Asih; Preeti Dave; Candice ManYan; Kevin Taddei; David B Lovejoy; Roger Chung; Gilles J Guillemin; Ralph N Martins
Journal:  Sci Rep       Date:  2018-05-22       Impact factor: 4.379

8.  Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.

Authors:  Todd A Johnson; H A Jinnah; Naoyuki Kamatani
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

9.  Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.

Authors:  Pratishtha Chatterjee; Henrik Zetterberg; Kathryn Goozee; Chai K Lim; Kelly R Jacobs; Nicholas J Ashton; Abdul Hye; Steve Pedrini; Hamid R Sohrabi; Tejal Shah; Prita R Asih; Preeti Dave; Kaikai Shen; Kevin Taddei; David B Lovejoy; Gilles J Guillemin; Kaj Blennow; Ralph N Martins
Journal:  J Neuroinflammation       Date:  2019-10-10       Impact factor: 8.322

Review 10.  Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development.

Authors:  Knut Biber; Anindya Bhattacharya; Brian M Campbell; Justin R Piro; Michael Rohe; Roland G W Staal; Robert V Talanian; Thomas Möller
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.